



Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?

Editorial Office

Translational Lung Cancer Research

Correspondence to: Editorial Office, Translational Lung Cancer Research. Email: editor@tlcr.org.

Submitted Feb 03, 2023, Accepted for publication Feb 08, 2023. Published online Feb 20, 2023.

doi: 10.21037/tlcr-2023-2

View this article at: <https://dx.doi.org/10.21037/tlcr-2023-2>

Erratum to: *Transl Lung Cancer Res* 2022;11:2360-3

This article (1) titled “Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?” (doi: 10.21037/tlcr-22-828), unfortunately contains a few errors in the *Funding* and *Conflicts of Interest* statements. The corrections can be found below.

The funding statement should be changed from “*Funding*: None.” to “*Funding*: This work was supported in part by National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program.”.

The *Conflicts of Interest* statement should be changed from “*Conflicts of Interest*: Both authors have completed the ICMJE uniform disclosure form (available at <https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-828/coif>). The authors have no conflicts of interest to declare.” to “*Conflicts of Interest*: Both authors have completed the ICMJE uniform disclosure form (available at <https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-828/coif>). JJZ serves as an unpaid editorial board member of *Translational Lung Cancer Research* from October 2021 to September 2023. JJZ was supported by the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program. JJZ reports consulting fees from Johnson and Johnson, personal fees from Novartis, Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui, serves on board for Novartis, AstraZeneca, GenePlus, and received support from Novartis, Johnson and Johnson. ND has no conflicts of interest to declare.”.

Following this change, the COI form was updated.

The authors apologize for the oversight.

Click [here](#) to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Deboever N, Zhang J. Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much? *Transl Lung Cancer Res* 2022;11:2360-3.

Cite this article as: Editorial Office. Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much? *Transl Lung Cancer Res* 2023;12(2):393-394. doi: 10.21037/tlcr-2023-2